[A20-57] Ribociclib (breast cancer, combination with an aromatase inhibitor) - Addendum to commission A20-21
Last updated 20.08.2020
Project no.:
A20-57
Commission:
Commission awarded on 06.07.2020 by the Federal Joint Committee (G-BA).
Report type:
Addendum
Status:
Commission completed
Department/Division:
Drug Assessment
Application field:
Cancer
Indication:
| Initial endocrine therapy in postmenopausal women with HR-positive, HER2-negative locally advanced or metastatic breast cancer |
Result of dossier assessment:
| Conclusion of dossier assessment A20-21 unchanged: added benefit still not proven. |
Note:
If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.
| Project no. | Title | Status |
|---|---|---|
| A20-21 | Ribociclib (breast cancer; combination with aromatase inhibitors) - Benefit assessment according to §35a Social Code Book V | Commission completed |
Federal Joint Committee (G-BA)
20.08.2020 A G-BA decision was published.